scispace - formally typeset
Search or ask a question

Showing papers by "Joan H. Schiller published in 2019"

Journal Article•DOI•
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

[...]

Suresh S. Ramalingam1, Suzanne E. Dahlberg2, Chandra P. Belani3, Joel N. Saltzman4, Nathan A. Pennell5, Gopakumar S. Nambudiri6, John McCann7, Jerome D. Winegarden, Mohammed A. Kassem, Mohamed K. Mohamed8, Jan M. Rothman9, Alan P. Lyss10, Leora Horn11, Thomas E. Stinchcombe12, Joan H. Schiller •
Emory University1, Harvard University2, Penn State Milton S. Hershey Medical Center3, University Hospitals of Cleveland4, Cleveland Clinic5, St. John's University6, Baystate Medical Center7, Moses H. Cone Memorial Hospital8, University of Pittsburgh9, Missouri Baptist Medical Center10, Vanderbilt University11, Duke University12
30 Jul 2019-Journal of Clinical Oncology
TL;DR: The combination of bevacizumab and pemetrexed is efficacious as maintenance therapy for advanced nonsquamous NSCLC but cannot be recommended because of a lack of survival benefit and higher toxicity.
Abstract: PURPOSEPemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non–small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated effi...

45 citations

Journal Article•DOI•
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.

[...]

Tao Wang1, Rong Lu1, Sunny Lai1, Joan H. Schiller, Fang Liz Zhou, Bo Ci1, Stacy Wang1, Xiaohan Gao1, Bo Yao1, David E. Gerber1, David H. Johnson1, Guanghua Xiao1, Yang Xie1 •
University of Texas Southwestern Medical Center1
05 Apr 2019-Cancer Informatics
TL;DR: A nomogram model based on basic clinical features and routine lab testing predicts individual survival probabilities for advanced NSCLC and exhibits cross-study robustness.
Abstract: Importance:Nomogram prognostic models can facilitate cancer patient treatment plans and patient enrollment in clinical trials.Objective:The primary objective is to provide an updated and accurate p...

7 citations